| dc.identifier.citation | Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S, Engel U, Bartenschlager R. 2008. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 4(3): e1000035. Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, Ben Mami N, Triki H, Chouchane L. 2009. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy. J Med Virol 81(12): 2021-8. Enomoto N, Maekawa S. 2010. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 53(1): 66-9.Foster TL, Belyaeva T, Stonehouse NJ, Pearson AR, Harris M. 2010. All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J Virol 84(18): 9267-77. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 54(9): 3641-50. Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Maehara Y. 2010. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol 52(5): 672-80. Hinson ER, Cresswell P. 2009. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. Proc Natl Acad Sci U S A 106(48): 20452-7. Hughes M, Gretton S, Shelton H, Brown DD, McCormick CJ, Angus AG, Patel AH, Griffin S, Harris M. 2009a. A conserved proline between domains II and III of hepatitis C virus NS5A influences both RNA replication and virus assembly. J Virol 83(20): 10788-96. Hughes M, Griffin S, Harris M. 2009b. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 90(Pt 6):1329-34. Jenke AC, Moser S, Orth V, Zilbauer M, Gerner P, Wirth S. 2009. Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy. J Viral Hepat 16(12): 853-9. Kriegs M, Bürckstümmer T, Himmelsbach K, Bruns M, Frelin L, Ahlén G, Sällberg M, Hildt E. 2009. The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem 284(41): 28343-51. Kumthip K, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N. 2010. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat doi: 10.1111/j.1365-2893.2010.01379.x. Malta Fde M, Medeiros-Filho JE, Azevedo RS, Gonçalves L, Silva LC, Carrilho FJ, Pinho JR. 2010. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis. Mem Inst Oswaldo Cruz 105(1): 92-8. Mankouri J, Griffin S, Harris M. 2008. The hepatitis C virus non-structural protein NS5A alters the trafficking profile of the epidermal growth factor receptor. Traffic 9(9): 1497-509. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T. 2008. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 82(16): 7964-76. Okamoto T, Omori H, Kaname Y, Abe T, Nishimura Y, Suzuki T, Miyamura T, Yoshimori T, Moriishi K, Matsuura Y. 2008. A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J Virol 82(7): 3480-9. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H. 2009. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 44(9):952-63. Palomares-Jerez MF, Guillén J, Villalaín J. 2010. Interaction of the N-terminal segment of HCV protein NS5A with model membranes. Biochim Biophys Acta 1798(6): 1212-24. Peng L, Liang D, Tong W, Li J, Yuan Z. 2010. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 285(27): 20870-81. Puyang X, Poulin DL, Mathy JE, Anderson LJ, Ma S, Fang Z, Zhu S, Lin K, Fujimoto R, Compton T, Wiedmann B. 2010. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother 54(5): 1981-7. Shelton H, Harris M. 2008. Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction. J Virol 5:24. Tellinghuisen TL, Foss KL, Treadaway J. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 2008 Mar 21;4(3):e1000032. Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY, Liu CJ, Chen PJ, Hwang LH. 2008. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol 49(6): 899-907. Wang AG, Lee DS, Moon HB, Kim JM, Cho KH, Choi SH, Ha HL, Han YH, Kim DG, Hwang SB, Yu DY. 2009. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol 219(2): 253-62. Xu Z, Fan X, Xu Y, Di Bisceglie AM. 2008. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. J Virol 82(19):9417-24. Yuan HJ, Jain M, Snow KK, Gale M Jr, Lee WM; HALT-C Trial Group. 2010. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. J Viral Hepat 17(3): 208-16. | en_US |
| dc.description.abstract | The hepatitis C virus (HCV) NS5A protein is known essential for virus replication and suggested play important role in therapy resistance mechanism. To predict and more understanding the molecular pattern of HCV 1a NS5A we cloned the NS5A gene of HCV 1a isolated in Central of Java Indonesia using standard cloning procedure. The sequence results were then aligned with all of HCV 1a NS5A complete coding sequences reported in GenBank. In total, 441 sequences were retrieved and aligned by ClustalW. We revealed the nucleotide and amino acid sequence consensus of HCV NS5A gene. Overall, only aa 5, 9-11, 13-15, 18-19, 22-23, 25-27, 29, 32-33, 35, 38-43, 45, 47, 50-51, 55, 57, 59-60, 63, 65-67, 70, 72, 76, 80, 82, 84, 86, 88-91, 94-97, 100, 102, 104-106, 109-113, 115-116, 118-120, 125, 128-129, 132, 134, 136, 140-143, 145, 147, 149-152, 154-157, 159, 162-163, 165, 167-168, 170, 173, 175, 178-179, 184-187, 189-193, 195, 201, 203, 207-208, 210, 216-218, 220, 222-225, 227-235, 238, 243, 249, 252, 257, 268, 270, 271, 274, 278, 283, 291-292, 298, 300, 306, 309-311, 313-314, 318-321, 324, 326, 329, 331, 336, 338-339, 342, 348, 350, 353, 356, 360, 363, 368-369, 377, 405-406, 409, 411-414, 416-419, 421-424, 427, 430-432, and 443 were found have no variation. Amino acid variations may have relevant changes of physicochemical properties so that influence the replication efficiency, therefore, the amino acid variations found in the present report need further study | en_US |
